Electroretinogram: a new human biomarker for smoking cessation treatment

项目名称：视网膜电图：戒烟治疗的新人类生物标志物 项目摘要：在此申请K23指导的患者导向的研究职业发展 获奖后，Sean Luo博士提出了一个发展成为独立研究员的全面计划， 开发物质使用障碍，特别是烟草使用障碍的生物标志物。具体来说， 这项提案将集中于开发一种新的人类生物标志物，即多巴胺释放的视网膜电图。烟草 吸烟仍然是一个重大的公共卫生挑战。有证据表明多巴胺 尼古丁释放不足与尼古丁依赖的形成和维持有关。我们假设 那些没有多巴胺释放缺陷的吸烟者更有可能对行为治疗做出反应， 戒烟，特别是戒烟后的经济奖励（应急 管理）。以前的试验数据表明，闪光蓝锥视网膜电图（ERG），其中记录 来自视网膜的响应于光的电信号，是临床上可获得的与多巴胺释放的相关性， 大脑我们提出了一种基于ERG的生物标志物，并进行了一项试点临床试验，将这种生物标志物应用于个性化治疗。 戒烟治疗。这种临床上易于处理的中枢多巴胺释放生物标志物可能具有很大的 今后在诊断和治疗其他精神疾病和药物使用方面的应用数量 紊乱在与他的导师（爱德华·努内斯博士和爱德华·努内斯博士）的专业知识进行这一研究的同时， Frances Levin）和导师（Diana Martinez博士、Stephen Tsang博士、Alan Budney博士和Jill威廉姆斯博士）、罗博士 将同时从事个性化的培训计划，以便在以下重要领域发展： (1)视网膜生理学和生物标志物的开发（2）视网膜数据分析方法（3）临床研究 方法（4）烟草使用障碍的行为和药物治疗（5）批准写作和 局

Project Title: Electroretinogram: A New Human Biomarker for Smoking Cessation Treatment Project Summary: In this application for a K23 Mentored Patient Oriented Research Career Development Award, Dr. Sean Luo proposes a comprehensive plan for developing into an independent researcher to develop biomarkers in substance use disorders, and in particular, tobacco use disorder. Specifically, this proposal will focus on developing a new human biomarker, electroretinogram, for dopamine release. Tobacco smoking continues to be a major public health challenge. Several lines of evidence suggest that dopamine release deficit is involved in the development and maintenance of nicotine dependence. We hypothesize that those smokers who do not have a deficit in dopamine release will more likely respond to behavioral treatments for smoking cessation, and in particular, financial incentives contingent on abstinence (Contingency Management). Previous pilot data suggest that flash blue cone electroretinogram (ERG), which records electrical signals from the retina in response to light, is a clinically accessible correlate to dopamine release in the brain. We propose an ERG-based biomarker, and a pilot clinical trial to apply this biomarker to personalize smoking cessation treatment. This clinically tractable biomarker of central dopamine release may have a large number of future applications in the diagnosis and treatment of other mental illnesses and substance use disorders. While pursuing this line of research with the expertise of his mentors (Dr. Edward Nunes and Dr. Frances Levin) and preceptors (Drs. Diana Martinez, Stephen Tsang, Alan Budney and Jill Williams), Dr. Luo will concurrently engage in an individualized training program so as to develop in the following important areas: (1) retinal physiology and biomarker development (2) retinal data analytic methods (3) clinical research methods (4) behavioral and pharmacological treatment of tobacco use disorder (5) grant writing and administration.